

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Renal Dysfunction

Journal of the American Society of Nephrology: JASN
28, 1306-1313

DOI: [10.1681/asn.2016060640](https://doi.org/10.1681/asn.2016060640)

Citation Report

#	ARTICLE	IF	CITATIONS
1	IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 677-686.	2.2	358
2	An update on the treatment of IgA nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 319-326.	1.0	11
3	Inflammation in IgA nephropathy. <i>Pediatric Nephrology</i> , 2017, 32, 2215-2224.	0.9	38
4	Rituximab therapy for IgA nephropathy. <i>Nature Reviews Nephrology</i> , 2017, 13, 138-140.	4.1	4
5	Immunosuppression in IgA Nephropathy: Guideline Medicine Versus Personalized Medicine. <i>Seminars in Nephrology</i> , 2017, 37, 464-477.	0.6	7
6	Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. <i>Scientific Reports</i> , 2017, 7, 9091.	1.6	16
7	Corticosteroids for IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 429.	3.8	7
9	Nefropat�a IgA: �¿qu�a � pacientes est�n en riesgo de progresar a enfermedad renal terminal y c�mo deber�an ser tratados?. <i>Nefrolog�a</i> , 2018, 38, 347-352.	0.2	4
10	IgA Vasculitis in Adults. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 119-132.	0.6	3
11	Treatment of IgA nephropathy: Recent advances and prospects. <i>Nephrologie Et Therapeutique</i> , 2018, 14, S13-S21.	0.2	33
12	Bortezomib for Reduction of Proteinuria in �IgA Nephropathy. <i>Kidney International Reports</i> , 2018, 3, 861-866.	0.4	32
13	New insights into the pathogenesis of IgA nephropathy. <i>Pediatric Nephrology</i> , 2018, 33, 763-777.	0.9	97
14	Brief Report: Rituximab for the Treatment of Adult �nset IgA Vasculitis (Henoch � Sch �nlein). <i>Arthritis and Rheumatology</i> , 2018, 70, 109-114.	2.9	71
15	Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 317-325.	3.0	64
16	TESTING Corticosteroids in IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 158-160.	2.2	16
17	15th International Symposium on IgA Nephropathy � IgANN 2018, Buenos Aires, September 27-29, 2018: Summaries. <i>Kidney Diseases (Basel, Switzerland)</i> , 2018, 4, 145-194.	1.2	2
18	Update on treatment of immunoglobulin A nephropathy. <i>Nephrology</i> , 2018, 23, 62-67.	0.7	8
20	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39

#	ARTICLE	IF	CITATIONS
21	Treatment of IgA Nephropathy: Evolution Over Half a Century. <i>Seminars in Nephrology</i> , 2018, 38, 531-540.	0.6	17
22	Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment. <i>American Journal of Nephrology</i> , 2018, 47, 43-52.	1.4	27
23	IgA nephropathy: What patients are at risk of progression to end-stage renal disease and how should they be treated?. <i>Nefrologia</i> , 2018, 38, 347-352.	0.2	0
24	Insights into the Role of Mucosal Immunity in IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1584-1586.	2.2	35
25	Primary IgA nephropathy: current challenges and future prospects. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 137-148.	0.8	32
27	Treatment of systemic necrotizing vasculitides: recent advances and important clinical considerations. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 939-949.	1.3	4
29	Recurrent and de novo Glomerulonephritis After Kidney Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1944.	2.2	40
30	Childhood IgA Vasculitis (Henoch Schonlein Purpura) – Advances and Knowledge Gaps. <i>Frontiers in Pediatrics</i> , 2019, 7, 257.	0.9	119
31	Is it possible to predict the evolution of IgAN? Validation of the IgA nephropathy progression calculator and its relationship with MEST-C score in our population. <i>Nefrologia</i> , 2019, 39, 523-530.	0.2	0
32	Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1458-1465.	2.2	36
33	Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2017-2026.	3.0	72
34	Noninvasive Urinary Monitoring of Progression in IgA Nephropathy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4463.	1.8	8
35	Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2019, 10, 1990.	2.2	133
36	Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1584.	1.0	6
38	¿Es posible predecir la evolución de la nefropatía IgA? Validamos la calculadora de progresión de nefropatía IgA y su relación con Oxford score en nuestra población. <i>Nefrologia</i> , 2019, 39, 523-530.	0.2	2
39	Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 15-22.	2.1	106
41	Rituximab for Anti-“Glomerular Basement Membrane Disease. <i>Kidney International Reports</i> , 2019, 4, 614-618.	0.4	16
42	IgA Nephropathy: Clinical Features, Pathogenesis, and Treatment. , 2019, , 367-380.		1

#	ARTICLE	IF	CITATIONS
43	A proliferation-inducing ligand increase precedes IgA nephropathy recurrence in kidney transplant recipients. <i>Clinical Transplantation</i> , 2019, 33, e13502.	0.8	16
44	New strategies and perspectives on managing IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 577-588.	0.7	55
45	Towards a personalized treatment for IgA nephropathy considering pathology and pathogenesis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1832-1838.	0.4	20
46	T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 291-303.	0.7	57
47	Effector and regulatory B cells in immune-mediated kidney disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 11-26.	4.1	85
48	Immunoglobulin A Nephropathy and Immunoglobulin A Vasculitis. <i>Pediatric Clinics of North America</i> , 2019, 66, 101-110.	0.9	26
49	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
50	IgA Nephropathy. , 2019, , 107-128.		0
51	An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. <i>Kidney International Reports</i> , 2020, 5, 58-65.	0.4	17
52	Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 31.	0.7	11
53	Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies. <i>Theranostics</i> , 2020, 10, 11462-11478.	4.6	43
54	Emerging Modes of Treatment of IgA Nephropathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9064.	1.8	21
56	Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives. <i>International Journal of Biological Sciences</i> , 2020, 16, 2518-2526.	2.6	2
57	Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management. <i>Frontiers in Immunology</i> , 2020, 11, 572754.	2.2	24
58	Recurrent glomerulonephritis after renal transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 636-644.	1.0	3
59	Recurrence of immunoglobulin A nephropathy after kidney transplantation: a narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 758-767.	1.4	14
60	A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges. <i>Nephron</i> , 2020, 144, 555-571.	0.9	27
61	Why Target the Gut to Treat IgA Nephropathy?. <i>Kidney International Reports</i> , 2020, 5, 1620-1624.	0.4	37

#	ARTICLE	IF	CITATIONS
62	SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, <i>diabetic nephropathy</i> [™] , IgA nephropathy and podocytopathies with FSGS lesions. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1609-1615.	0.4	30
63	Immunosuppressive agents for treating IgA nephropathy. <i>The Cochrane Library</i> , 2020, 3, CD003965.	1.5	40
64	Rituximab treatment for IgA vasculitis: A systematic review. <i>Autoimmunity Reviews</i> , 2020, 19, 102490.	2.5	32
65	Cell junction proteins: Crossing the glomerular filtration barrier in diabetic nephropathy. <i>International Journal of Biological Macromolecules</i> , 2020, 148, 475-482.	3.6	48
66	New therapeutic perspectives for IgA nephropathy in children. <i>Pediatric Nephrology</i> , 2021, 36, 497-506.	0.9	12
67	Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021, 7, 50-56.	1.2	15
68	IgA Nephropathy: An Interesting Autoimmune Kidney Disease. <i>American Journal of the Medical Sciences</i> , 2021, 361, 176-194.	0.4	91
69	Increasing prescription of renin-angiotensin-aldosterone system blockers associated with improved kidney prognosis in Korean IgA nephropathy patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1673-1680.	1.4	0
70	The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 840-847.	0.4	18
71	Past and present of childhood kidney disease: advances in treatment based on the pathogenesis of pediatric IgA nephropathy. <i>Japanese Journal of Pediatric Nephrology</i> , 2021, 34, 21-31.	0.0	0
72	Weighted Gene Co-expression Network Analysis Reveals Different Immunity but Shared Renal Pathology Between IgA Nephropathy and Lupus Nephritis. <i>Frontiers in Genetics</i> , 2021, 12, 634171.	1.1	6
73	Expression profile of Fc receptor-like molecules in patients with IgA nephropathy. <i>Human Immunology</i> , 2021, 82, 186-192.	1.2	0
75	Enumerating the role of properdin in the pathogenesis of IgA nephropathy and its possible therapies. <i>International Immunopharmacology</i> , 2021, 93, 107429.	1.7	7
76	IgA vasculitis with nephritis: update of pathogenesis with clinical implications. <i>Pediatric Nephrology</i> , 2022, 37, 719-733.	0.9	35
77	IgA Nephropathy: "The Times They Are a-Changin". <i>Complex Psychiatry</i> , 2022, 2, 4-14.	1.3	1
78	Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression. <i>Nefrologia</i> , 2021, 41, 311-320.	0.2	3
79	IgA Vasculitis and IgA Nephropathy: Same Disease?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2310.	1.0	31
80	La determinación de IgA1 galactosil deficiente mediante el anticuerpo monoclonal KM55 contribuye a predecir a los pacientes con nefropatía IgA con alto riesgo de progresión a largo plazo. <i>Nefrologia</i> , 2021, 41, 311-320.	0.2	3

#	ARTICLE	IF	CITATIONS
81	Recurrent glomerulonephritis after kidney transplantation: a practical approach. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 360-380.	0.8	7
82	Assessing Patient Preferences in Rare Diseases: Direct Preference Elicitation in the Rare Chronic Kidney Disease, Immunoglobulin A Nephropathy. <i>Patient</i> , 2021, 14, 837-847.	1.1	3
83	Tonsillectomy Combined With Steroid Pulse Therapy Prevents the Progression of Chronic Kidney Disease in Patients With Immunoglobulin A (IgA) Nephropathy in a Single Japanese Institution. <i>Cureus</i> , 2021, 13, e15736.	0.2	2
84	An Update on the Current State of Management and Clinical Trials for IgA Nephropathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2493.	1.0	31
85	Role of the intestinal MALT in pathogenesis of the IgA-nephropathy. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 724-728.	0.2	0
86	Precision medicine in immunoglobulin A nephropathy: still a journey ahead. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 24-30.	0.4	4
87	IgA vasculitis. <i>Seminars in Immunopathology</i> , 2021, 43, 729-738.	2.8	61
88	Shared genetic study gives insights into the shared and distinct pathogenic immunity components of IgA nephropathy and SLE. <i>Molecular Genetics and Genomics</i> , 2021, 296, 1017-1026.	1.0	4
89	Immunoglobulin A vasculitis: challenging renal implications of adult onset. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2021, 180, .	0.0	0
90	Glomerulonefritis rápidamente progresiva mediada por inmunocomplejos (tipo II). Revisión de la literatura. <i>Medicina Y Laboratorio</i> , 2021, 25, 569-580.	0.0	0
91	IgA Vasculitis in Adults: a Rare yet Challenging Disease. <i>Current Rheumatology Reports</i> , 2021, 23, 50.	2.1	14
92	How immunosuppressive drugs may directly target podocytes in glomerular diseases. <i>Pediatric Nephrology</i> , 2022, 37, 1431-1441.	0.9	4
93	Comparative Long-Term Renal Allograft Outcomes of Recurrent Immunoglobulin A with Severe Activity in Kidney Transplant Recipients with and without Rituximab: An Observational Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3939.	1.0	3
95	An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective. <i>Frontiers in Pharmacology</i> , 2021, 12, 715253.	1.6	23
96	Management of IgA Vasculitis with Nephritis. <i>Paediatric Drugs</i> , 2021, 23, 425-435.	1.3	5
97	Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don't Know. <i>Journal of Clinical Medicine</i> , 2021, 10, 3467.	1.0	24
98	Current treatment of IgA nephropathy. <i>Seminars in Immunopathology</i> , 2021, 43, 717-728.	2.8	52
99	Therapeutic and delivery strategies of phytoconstituents for renal fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113911.	6.6	15

#	ARTICLE	IF	CITATIONS
100	New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy. <i>Glomerular Diseases</i> , 2022, 2, 15-29.	0.2	3
103	Development and validation of a prognostic nomogram for IgA nephropathy. <i>Oncotarget</i> , 2017, 8, 94371-94381.	0.8	6
104	Recent advances in risk prediction, therapeutics and pathogenesis of IgA nephropathy. <i>Minerva Medica</i> , 2019, 110, 439-449.	0.3	9
105	Management of IgA vasculitis nephritis (Henoch-Schonlein purpura nephritis) in Children. <i>Childhood Kidney Diseases</i> , 2020, 24, 1-13.	0.1	2
106	Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. <i>Nephrology (Saint-Petersburg)</i> , 2020, 24, 22-41.	0.1	10
107	Use of Rituximab in Management of Rapidly Progressive Glomerulonephritis. <i>Cureus</i> , 2020, 12, e6820.	0.2	2
108	The mucosal immune system and IgA nephropathy. <i>Seminars in Immunopathology</i> , 2021, 43, 657-668.	2.8	46
109	IgA Nephropathy - Clinical Features, Pathogenesis, and Treatment. , 2017, , 1-14.		0
111	Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link. <i>International Journal of Immunogenetics</i> , 2022, 49, 8-21.	0.8	21
112	A Case Series of Adult Patients Diagnosed with IgA Vasculitis Requiring Systemic Immunosuppression. <i>American Journal of Case Reports</i> , 2021, 22, e933407.	0.3	4
113	Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics. <i>Advances in Immunology</i> , 2021, 152, 1-81.	1.1	7
114	Use of Rituximab as an off-Label medication in Glomerular Diseases: Clinical Perspective. <i>Medical Principles and Practice</i> , 2022, , .	1.1	1
115	Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case. <i>Pediatric Nephrology</i> , 2022, 37, 1597-1603.	0.9	1
116	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. <i>Kidney International Reports</i> , 2022, 7, 993-1003.	0.4	18
117	Adult-Onset Immunoglobulin A Vasculitis With Renal Involvement. <i>Cureus</i> , 2022, 14, e23649.	0.2	0
118	The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov. <i>Renal Failure</i> , 2022, 44, 461-472.	0.8	6
119	New Insights into the Treatment of Glomerular Diseases: When Mechanisms Become Vivid. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3525.	1.8	8
120	Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 873-875.	3.0	6

#	ARTICLE	IF	CITATIONS
121	Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function. CKJ: Clinical Kidney Journal, 2022, 15, 771-777.	1.4	6
126	Acute glomerulonephritis. Lancet, The, 2022, 399, 1646-1663.	6.3	24
127	New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. Journal of Clinical Medicine, 2022, 11, 2810.	1.0	15
128	Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial. Trials, 2022, 23, .	0.7	3
130	Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria. Kidney International Reports, 2022, 7, 1831-1841.	0.4	32
131	Immunosuppressive therapy for IgA nephropathy in children. The Cochrane Library, 2022, 2022, .	1.5	0
132	Establishment of Membrane-Bound IgA1-Specific Antibody Possessing Antibody-Dependent Cellular Cytotoxicity Activity. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 125-132.	0.8	0
133	Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis. Frontiers in Pharmacology, 0, 13, .	1.6	3
134	Immunoglobulin A Nephropathy in Children. , 2022, , 437-463.		0
135	The New Progress of Treatment in IgA Nephropathy. Advances in Clinical Medicine, 2022, 12, 7032-7041.	0.0	0
136	Orange-derived and dexamethasone-encapsulated extracellular vesicles reduced proteinuria and alleviated pathological lesions in IgA nephropathy by targeting intestinal lymphocytes. Frontiers in Immunology, 0, 13, .	2.2	7
137	Current Treatment for IgA Nephropathy and Its Rationale. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2286-2292.	0.0	0
138	Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Frontiers in Immunology, 0, 13, .	2.2	8
140	IgA nephropathy: an overview of drug treatments in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 1321-1338.	1.9	8
141	IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment. Diagnostics, 2023, 13, 303.	1.3	9
142	A mixed-method evaluation of the relationship between Oxford classification scores and longitudinal changes in proteinuria in patients with immunoglobulin A nephropathy. Frontiers in Endocrinology, 0, 13, .	1.5	2
143	Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney International Reports, 2023, 8, 499-506.	0.4	20
144	IgA Nephropathy with Macroproteinuria and a CFR of 20-30â€‰ml/min/1.73â€‰m ² May Still Benefit from RAS Inhibition. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2022, 2022, .	1.0	0

#	ARTICLE	IF	CITATIONS
145	Immune abnormalities in IgA nephropathy. CKJ: Clinical Kidney Journal, 2023, 16, 1059-1070.	1.4	7
146	Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning. Frontiers in Endocrinology, 0, 14, .	1.5	3
147	Efficacy and safety of sequential immunosuppressive treatment for severe IgA nephropathy: A retrospective study. Frontiers in Pharmacology, 0, 14, .	1.6	0
148	Current status and perspectives on recurrent IgA nephropathy after kidney transplantation. Nephron, 0, , .	0.9	2
149	The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. BMC Nephrology, 2023, 24, .	0.8	2
150	IgA Nephropathy. , 2023, , 509-530.		0
161	A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). Clinical Rheumatology, 0, , .	1.0	0
165	Clinical advances in immunotherapy for immune-mediated glomerular diseases. Clinical and Experimental Medicine, 2023, 23, 4091-4105.	1.9	0
171	Kidney transplantation: the recipient. , 2024, , 411-691.		0